Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Future Medicine Ltd  (3)
Type of Medium
Publisher
  • Future Medicine Ltd  (3)
Language
Years
  • 1
    Online Resource
    Online Resource
    Future Medicine Ltd ; 2006
    In:  Aging Health Vol. 2, No. 4 ( 2006-08), p. 559-570
    In: Aging Health, Future Medicine Ltd, Vol. 2, No. 4 ( 2006-08), p. 559-570
    Abstract: With the introduction of phosphodiesterase type-5 inhibitors as a first-line, oral treatment for erectile dysfunction, intracavernous injection of vasoactive agents is regarded as a secondary therapy for most patients. However, clinicians evaluating the aging male must be aware of this important group of safe and effective therapies, since patients may be more appropriately treated for their erectile dysfunction with intracavernous prostaglandin E-1, papaverine or phentolamine (alone or in combination) owing to the presence of absolute contraindications to phosphodiesterase type-5 use, a failure to respond to these agents or patient preference. Ongoing research continues to define new options for the intracavernous treatment of erectile dysfunction, including gene transfer therapy. These efforts will probably result in the introduction of novel therapies with greater efficacy, tolerability and a more rapid onset of action, as an ever-expanding number and combination of agents is investigated. Until then, contemporary intracavernous vasoactive treatments will continue to successfully restore erectile function among patients with diverse erectile dysfunction etiologies and a variety of comorbidities.
    Type of Medium: Online Resource
    ISSN: 1745-509X , 1745-5103
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2006
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Future Medicine Ltd ; 2005
    In:  Aging Health Vol. 1, No. 2 ( 2005-10), p. 203-214
    In: Aging Health, Future Medicine Ltd, Vol. 1, No. 2 ( 2005-10), p. 203-214
    Abstract: Oral phosphodiesterase type-5 inhibitors are the contemporary choice for first-line treatment of erectile dysfunction in most men. Due to its efficacy, safety and ease-of-use, tadalafil is preferred by many men suffering from erectile dysfunction of varying severity and etiology. In this review, pharmacodynamic and updated clinical data from integrated analyses and postmarketing surveillance of tadalafil are reported, including efficacy results for specific patient subpopulations, treatment guidelines and compiled safety data including a review of nonarteritic anterior ischemic optic neuropathy and possible links to the use of phosphodiesterase-5 inhibitors.
    Type of Medium: Online Resource
    ISSN: 1745-509X , 1745-5103
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2005
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Aging Health, Future Medicine Ltd, Vol. 3, No. 4 ( 2007-08), p. 527-542
    Abstract: This article reviews contemporary treatment strategies for the aging male who does not demonstrate a satisfactory response to first-line oral phosphodiesterase-5 inhibitor agents for erectile dysfunction. More than half of men aged 40–70 years are unable to attain or maintain a penile erection sufficient for satisfactory sexual performance, with the prevalence of erectile dysfunction climbing to more than 75% among those aged over 70 years. However, the aging male may fail to respond to or express dissatisfaction with oral on-demand treatment. Clinically effective phosphodiesterase-5 inhibitor salvage strategies include patient re-education, lifestyle changes, correction of risk factors, dose adjustment, agent switching, androgen replacement and/or psychosexual or relationship counseling. Important new data supporting the safe and efficacious use of daily phosphodiesterase-5 inhibitor dosing schedules are reviewed. If required, progression to second- and third-line treatments is appropriate for most men, and may include intracavernous penile injections, vacuum erection devices, multimodality therapy or implantation of a penile prosthesis.
    Type of Medium: Online Resource
    ISSN: 1745-509X , 1745-5103
    Language: English
    Publisher: Future Medicine Ltd
    Publication Date: 2007
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages